Skip to Content

Vita 34 AG VTIAF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Vita 34 AG is a Germany based umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The organization operates in the business segment of Stem Cell Banking, which is active in the field of collecting, processing and storing stem cells from umbilical cord blood and tissue, as well as the development of cell therapy processes. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.

Contact
Deutscher Platz 5a
Leipzig, D-04103, Germany
T +49 3414879240
Sector Healthcare
Industry Medical Care Facilities
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 117